Welcome and Introduction
Importance of Molecular Testing in NSCLC and Practical Considerations for Clinical Practice
Treatment Options for The Most Common Targetable Biomarkers for Advanced NSCLC: EGFR, KRAS, and HER2
Selecting Therapy for Less Common Driver Mutations in Advanced Lung Cancer: ALK, ROS, RET, TRK, and MET
Audience Question and Answer Session and Final Thoughts
Date / Time
Sheraton Grand Chicago
Todd M. Bauer, MD
Senior Investigator, Drug Development
Sarah Cannon Research Institute
Tennessee Oncology, PLLC
Narjust Duma, MD
Associate Director of the Cancer Care Equity Program
The Lowe Center for Thoracic Oncology
Dana-Farber Cancer Institute
Brigham and Women’s Hospital
Karen L. Reckamp, MD, MS
Professor of Medicine
Director, Division of Medical Oncology
Department of Medicine
Los Angeles, California
The goal of this program is to improve the knowledge and competence of learners to optimally assess biomarkers and then effectively and safely integrate novels agents into their practice for patients with NSCLC.
This educational program is intended for medical oncologists and other healthcare professionals who treat patients with NSCLC.
Upon completion of this activity, participants should be able to:
- Plan individualized treatment strategies for patients with advanced NSCLC based on available evidence, expert recommendations, and tumor molecular profile
- Discuss the practical aspects of biomarker testing and interpretation, including benefits/limitations of different testing methodologies/platforms/assays, along with racial, age, and socioeconomic disparities
- Assess all patients with advanced NSCLC for appropriate currently available biomarkers to guide treatment selection and clinical trial eligibility
- Summarize the available data and expert recommendations to determine which biomarkers should be tested in your patients with lung cancer
Joint Accreditation Statement
In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Physician Continuing Medical Education
Designation of Credit
CCO designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.